Sugi Predict

Sugi Predict / Compounds / SCHEMBL6896206

SCHEMBL6896206

SCHEMBL6896206

COC1(CO)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NR1H2 P55055 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ EPHX2 P34913 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ RECQL P46063 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ PIK3R1 P27986 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ TACR1 P25103 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29770724 0.91 PIK3R1 (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL15742968 0.88 USP2 (0.45) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL19156954 0.87 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL2943334 0.87 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL12113151 0.86 USP2 (0.46) USP2SMN1; SMN2HPGDEPHX2CTSK
SCHEMBL21888789 0.83 NR1H2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL15740512 0.83 USP2 (0.44) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL15076622 0.83 USP2 (0.44) USP2SMN1; SMN2HPGDEPHX2CTSK
SCHEMBL5523316 0.83 USP2 (0.44) USP2SMN1; SMN2HPGDEPHX2CTSK
SCHEMBL17447773 0.83 USP2 (0.44) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4606803-A1 KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) 2025-08-27 — — EP disclosed
WO-2025123318-A1 TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2025-06-19 — — WO disclosed
WO-2025124415-A1 TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS NIKANG THERAPEUTICS INC. (US) 2025-06-19 — — WO disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 — — US disclosed
WO-2024083258-A1 KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR 上海领泰生物医药科技有限公司 2024-04-25 — — WO disclosed
CN-117917416-A KRAS G12D degradation agent and preparation method and application thereof 上海领泰生物医药科技有限公司 2024-04-23 — — CN disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 — — WO disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 — — US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 — — US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 — — US disclosed
EP-2565194-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2013-03-06 — — EP disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 — — US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 — — US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 — — US disclosed
WO-2011136192-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-11-03 — — WO disclosed
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 — — US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 — — US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 — — US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 USP2 3888/4885SMN1; SMN2 2803/4885NR1H2 1838/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 USP2 2482/4885SMN1; SMN2 3406/4885NR1H2 1934/4885
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C USP2 2137/4885SMN1; SMN2 2352/4885NR1H2 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.